[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565533":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":50,"collaborators":25,"id":54,"slug":25,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":25,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Queen Mary Hospital, Hong Kong","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Timolol combination treatment","ACTIVE_COMPARATOR","Patients will received topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[13,14],"Drug: Timolol 0.5% eye drops and betamethasone valerate 0.1% cream","Drug: Betamethasone valerate 0.1% cream",{"label":16,"type":6,"description":17,"interventionNames":18},"Routine Arm","Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Timolol 0.5% eye drops and betamethasone valerate 0.1% cream","Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Betamethasone valerate 0.1% cream","The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.",[16,9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Wang Chun Kwok","CONTACT","+85222555336","kwokwch@hku.hk",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Queen Mary Hospital","RECRUITING","Hong Kong",{"type":42,"coordinates":43},"Point",[44,45],114.17469,22.27832,{"lat":45,"lon":44},[48],{"name":25,"role":33,"phone":49,"phoneExt":25,"email":25},"85222555336",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Kwok Wang Chun","Clinical Assistant Professor","100565533",false,"NCT06643416","Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial","Inclusion criteria\n\n1. Aged 18 years or above, either males or females.\n2. Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.\n3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use\n4. Written informed consent obtained from patient\n5. Subjects are diagnosed with advanced non-small cell lung cancer\n\nExclusion criteria\n\n1. 1\\. Age below18\n2. 2\\. Patients who are allergic to, or contraindicated to topical timolol use\n3. 3\\. Pregnant women or nursing mother\n4. 4\\. Non-consenting patients\n5. 5\\. Subjects are not diagnosed with advanced non-small cell lung cancer","ALL","18 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.",[70,71,72],"Paronychia","EGFR-TKI","ALK-TKI",[74,75,76,72],"EGFR TKI","paronychia","timolol","2024-10-16",{"date":79,"type":80},"2024-10-18","ACTUAL",{"date":82,"type":64},"2024-10-09",{"date":84,"type":64},"2025-12-31",{"name":5,"class":6},1]